Dan Parsley
Managing Partner @ Green Park & Golf Ventures
Houston, United States
Dan Parsley is a seed investor at Green Park & Golf Ventures in Houston focused on Health Care and Medical Device. Dan Parsley is the Managing Partner at GPG Ventures. Dan Parsley attended University of Virginia Darden School of Business.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Dan Parsley invests in
Stages Dan Parsley invests in
Countries Dan Parsley invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Medical Device 2 (67%)
- Medical 1 (33%)
- Life Science 1 (33%)
- Biotechnology 1 (33%)
Stage
- Seed 1 (33%)
- Funding Round 1 (33%)
- Convertible Note 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Noninvasix
|
Noninvasix, Inc. (the “Company” or “Noninvasix”) is a medical technology company that has developed a novel solution to non-invasively monitor for the first time, oxygen sufficiency in organs and veins. The Company was founded in 2007 by Dr. Donald Prough and Dr. Rinat Esenaliev at the University of Texas Medical Branch (UTMB) and is based out ofHouston, Texas. The Company has raised over $4.8 million to date including an oversubscribed $2 million seed round in Q2 2020. The platform technology of the Company has been developed with $6 million in grants from the NIH and DOD. The Company has also been a part of prestigious accelerator programs such as Philips Healthworks, TMCx, JLabs, Health Wildcatters and has won multiple awards for their innovation. The non-invasive technology has been clinically validated in multiple peer-reviewed journals. FDA pre-submission has been completed and the FDA has agreed for a De-novo clearance pathway. The IP portfolio of the Company includes 30 worldwide patents and 10 U.S. patents. | $2M / Feb 04, 2021 | |
|
Noninvasix
|
Noninvasix, Inc. (the “Company” or “Noninvasix”) is a medical technology company that has developed a novel solution to non-invasively monitor for the first time, oxygen sufficiency in organs and veins. The Company was founded in 2007 by Dr. Donald Prough and Dr. Rinat Esenaliev at the University of Texas Medical Branch (UTMB) and is based out ofHouston, Texas. The Company has raised over $4.8 million to date including an oversubscribed $2 million seed round in Q2 2020. The platform technology of the Company has been developed with $6 million in grants from the NIH and DOD. The Company has also been a part of prestigious accelerator programs such as Philips Healthworks, TMCx, JLabs, Health Wildcatters and has won multiple awards for their innovation. The non-invasive technology has been clinically validated in multiple peer-reviewed journals. FDA pre-submission has been completed and the FDA has agreed for a De-novo clearance pathway. The IP portfolio of the Company includes 30 worldwide patents and 10 U.S. patents. | $2M / Seed / Feb 04, 2021 | |
NovaScan
|
NovaScan provides diagnostic products that apply bioelectrical impedance to assess tissue characteristics relevant to cancer detection. Its MarginScan device performs ex vivo and in vivo margin evaluation by generating immediate electrical measurements during clinical procedures. The nsCanary tool examines biopsy cores directly after sampling toindicate whether malignant tissue is present. NovaScan also uses machine-learning models to interpret impedance signatures and distinguish cancerous from non-cancerous tissue. These products are designed to support clinical decision-making through rapid, instrument-based analysis. | $3M / Convertible Note / Jan 22, 2021 |
Co-Investors
Green Park & Golf, built on over 50 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm iscurrently looking for investment opportunities in medical-related start-ups.Dr. Heighten founded MedicalEdge Healthcare Group in 1993, and Mr. Soderstrom started PhyServe Physician Services in 1998 to administer the financial and operational needs of MedicalEdge. Together, the companies managed over 550 providers in five major markets. In 2011, the companies were sold to Texas Health Resources, a $3.8 billion health care system. That’s when Green Park & Golf was born.After earning his MBA at Southern Methodist University, Mr. Garcia joined them full-time in May 2011 to actively pursue new investment opportunities and monitor other investments in their portfolio. He has prior professional experience at FedEx, Bold Ventures, and Lone Star Investment Advisors.
Green Park & Golf Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carl Soderstrom
Founding Partner
|
|||
Claire England
Investment Partner
|
|||
Clay Heighten
Founding Member
|
|||
|
Dan Parsley
Managing Partner
|
|||
JR Garcia
Principal & VP of Investments
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dan Parsley invest in?
Dan Parsley invests primarily in Health Care, Medical Device and Medical startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dan Parsley?
Public channels for Dan Parsley include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dan Parsley last invest?
The most recent investment recorded for Dan Parsley closed in Feb 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
